Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07294170 · ClinicalTrials.gov registry record
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
A clinical trial of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
- Recruiting
- Registry status
- 70
- Enrollment target
- 5
- Study locations
NCT07294170: Recruiting study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
NCT07294170 is a study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 70 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07294170, a study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 5
- Study locations
Study Summary
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- BIOLOGICAL Empasiprubart IV
Study Locations (5)
California
- Profound Research LLC - Carlsbad - Carlsbad
Florida
- Visionary Investigators Network - Miami
Maryland
- Erlanger Health System - Columbia
New York
- Dent Neurologic Institute - Amherst - Amherst
Texas
- National Neuromuscular Research Institute - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-03-07 |
What NCT07294170 shows while recruiting
NCT07294170 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower).
The record links to 6 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT07294170 lists 5 locations in 5 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT07294170 about?
NCT07294170 is a clinical study titled "ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis". ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
What is the current status of trial NCT07294170?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2025-12-19. Estimated completion is 2028-03-07.
What conditions does trial NCT07294170 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis, gMG, Generalized Myasthenia Gravis (gMG), MG.
What interventions are being tested in trial NCT07294170?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Empasiprubart IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07294170?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07294170 being conducted?
This trial has 5 study locations across California, Florida, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07294170's enrollment target sits among peer trials
70 19th of 32 higher than 13 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
RECRUITING · NA
-
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI